Frederic Winssinger - USANA Health Independent Director
| USNA Stock | USD 47.10 1.55 3.40% |
Director
Mr. Frederic J. Winssinger is Independent Director of USANA Health Sciences, Inc. Mr. Winssinger became a director in May 2016. Mr. Winssinger was a Managing Partner of RW Partners LLC since 2006. RWP is a commercial real estate private equity investment company based in Phoenix, Arizona. Mr. Winssinger also oversees his family general investment operations and in 2014, he cofounded PlanninCore Wealth Advisors to provide investment advice to individuals and families. Prior to 2006, Mr. Winssinger worked in strategy consulting for the Boston Consulting Group and as a Portfolio ManagerFinancial Analyst for JP Morgan Asset Management and other privately held asset management companies. Mr. Winssinger received a B.A. in Mathematics and Economics from Claremont McKenna College and an M.B.A from The Wharton School of the University of Pennsylvania. Mr. Winssinger qualifications to sit on our Board include his 20 years of experience in financial analysis, and his training in evaluating corporate strategy towards the creation of shareholder value under sound corporate governance. since 2016.
| Age | 52 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Address | 3838 West Parkway Boulevard, Salt Lake City, UT, United States, 84120 |
| Phone | 801 954 7100 |
| Web | https://www.usana.com |
USANA Health Management Efficiency
The company has return on total asset (ROA) of 0.092 % which means that it generated a profit of $0.092 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1297 %, meaning that it created $0.1297 on every $100 dollars invested by stockholders. USANA Health's management efficiency ratios could be used to measure how well USANA Health manages its routine affairs as well as how well it operates its assets and liabilities. At present, USANA Health's Return On Tangible Assets are projected to slightly decrease based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.25, whereas Return On Capital Employed is forecasted to decline to 0.26. At present, USANA Health's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 37.4 M, whereas Non Current Assets Total are forecasted to decline to about 110.9 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| John Morrissey | Independent Bank | 50 | |
| Jane Lundquist | Independent Bank | 61 | |
| Peter Stanley | J J Snack | 75 | |
| Ellen Taaffe | John B Sanfilippo | 55 | |
| Claudia Poccia | Innospec | N/A | |
| Maurice Sullivan | Independent Bank | 69 | |
| Dennis Moore | J J Snack | 62 | |
| Lawrence Padfield | Innospec | 62 | |
| Vincent Melchiorre | J J Snack | 57 | |
| Michael Hogan | Independent Bank | 57 | |
| Thomas Venables | Independent Bank | 63 | |
| John Spurr | Independent Bank | 70 | |
| Christina Keller | Independent Bank | N/A | |
| Maria Harris | Independent Bank | 53 | |
| William Bissonnette | Independent Bank | 70 | |
| William Parent | Independent Bank | 56 | |
| Eileen Miskell | Independent Bank | 59 | |
| Carl Ribeiro | Independent Bank | 70 | |
| Frederick Taw | Independent Bank | 67 | |
| Martin Hale | Innospec | 73 | |
| John Gavin | Dorman Products | 61 | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.092 |
USANA Health Sciences Leadership Team
Elected by the shareholders, the USANA Health's board of directors comprises two types of representatives: USANA Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of USANA. The board's role is to monitor USANA Health's management team and ensure that shareholders' interests are well served. USANA Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, USANA Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Wood, Independent Director | ||
| David Wentz, Co-CEO | ||
| G Iiekking, CFO | ||
| Andrew Masuda, Director Relations | ||
| Scott Nixon, Additional Independent Director | ||
| Patrique Richards, Executive Development | ||
| Donald Williams, Independent Director | ||
| Paul Jones, CFO, Principal Accounting Officer and Chief Leadership Devel. Officer | ||
| Peggie Pelosi, Independent Director | ||
| Frederic Winssinger, Independent Director | ||
| Joshua Foukas, General Officer | ||
| Jerry McClain, Independent Director | ||
| Douglas Hekking, Chief Officer | ||
| James Bramble, Chief Legal Officer and Corporate Secretary | ||
| John Cuomo, Executive Technology | ||
| Douglas Braun, Chief Marketing Officer | ||
| Walter Noot, Chief Operating Officer | ||
| Brian Dixon, Executive Education | ||
| Deborah Woo, President of Asia and Greater China | ||
| Richard Williams, Independent Director | ||
| P Foukas, Chief Legal Officer, General Counsel and Corporate Secretary | ||
| Ronald Poelman, Board Secretary, Independent Director | ||
| Donald Wiiliam, Independent Director | ||
| Josh Foukas, Executive Vice President - Legal | ||
| Feng Peng, Independent Director | ||
| Kevin Guest, Chairman of the Board, Chief Executive Officer | ||
| Xia Ding, Independent Director | ||
| Daniel Macuga, Chief Communications and Marketing Officer | ||
| Robert Anciaux, Independent Director | ||
| David Mulham, Chief Field Development Officer | ||
| Gilbert Fuller, Lead Independent Director | ||
| Myron Wentz, Founder and Chairman | ||
| John Fleming, Independent Director | ||
| Jim Brown, Chief Production Officer | ||
| Brent Neidig, Chief Officer and Managing Director of China | ||
| G Hekking, Chief Financial Officer | ||
| Robert Sinnott, Chief Scientific Officer | ||
| Robert Auciaux, Independent Director | ||
| Dr MNS, Chief Officer |
USANA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is USANA Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.092 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.11 % | ||||
| Current Valuation | 546.36 M | ||||
| Shares Outstanding | 19.24 M | ||||
| Shares Owned By Insiders | 41.00 % | ||||
| Shares Owned By Institutions | 55.83 % | ||||
| Number Of Shares Shorted | 260.23 K | ||||
| Price To Earning | 8.70 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| CRM | Salesforce | |
| GOOG | Alphabet Inc Class C |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in USANA Health Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for USANA Stock analysis
When running USANA Health's price analysis, check to measure USANA Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy USANA Health is operating at the current time. Most of USANA Health's value examination focuses on studying past and present price action to predict the probability of USANA Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move USANA Health's price. Additionally, you may evaluate how the addition of USANA Health to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is USANA Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of USANA Health. If investors know USANA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about USANA Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.1) | Earnings Share 3.21 | Revenue Per Share 46.843 | Quarterly Revenue Growth (0.08) | Return On Assets 0.092 |
The market value of USANA Health Sciences is measured differently than its book value, which is the value of USANA that is recorded on the company's balance sheet. Investors also form their own opinion of USANA Health's value that differs from its market value or its book value, called intrinsic value, which is USANA Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because USANA Health's market value can be influenced by many factors that don't directly affect USANA Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between USANA Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if USANA Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, USANA Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.